Skip to content

Source filing unavailable

Q2 2013 · —
Revenue$208.25M+67.6% vs Q2 2012+6.1% vs Q1 2013
Net Income$42.19M+55.4% vs Q2 2012−2.9% vs Q1 2013
EPS Diluted$0.69+53.3% vs Q2 2012−2.8% vs Q1 2013
Gross Profit$181,533,000+64.0%
Operating Income$77,066,000+95.5%
Operating Cash Flowderived$8,719,000−88.7%
Free Cash Flowderived$5,152,000−93.1%
Margins · derived
Gross margin87.2%−1.9 pt vs Q2 2012
Operating margin37.0%+5.3 pt vs Q2 2012
Net margin20.3%−1.6 pt vs Q2 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2013Q2 2012Q2 2011Q2 2010
Revenue$208.25M$124.23M$64.57M$64.57M
Net Income$42.19M$27.15M$33.20M$33.20M
EPS Diluted$0.69$0.45$0.71$0.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR